TABLE 2.

Outcomes (90-day survival) of patients stratified by the immunosuppressive and antifungal agents received

Drug combination (n)aSurvivala in CI recipients when drugs were:Survivala of non-CI recipients
SynergisticAdditive
Tacrolimus + AmB (31)25/30 (83)1/1 (100)
CsA + AmB (8)7/7 (100)1/1 (100)
Non-CI + AmB (9)5/9 (56)
Tacrolimus + fluconazole (14)10/10 (100)4/4 (100)
CsA + fluconazole (3)3/3 (100)
Non-CI + fluconazole (4)3/4 (75)
Any CI (56)45/50 (90)6/6 (100)
Any non-CI (13)8/13 (62)
Total (69)45/50 (90)6/6 (100)8/13 (62)
  • a Each value in parentheses is the number of patients who received the drug combination.

  • bData are presented for 69 of the 74 study patients; 2 patients who received a CI were not treated (diagnosed at autopsy), and 3 received an antifungal agent other than AmB or fluconazole as therapy for cryptococcosis.